Quibim, S.L.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Quibim, S.L. - overview
Established
2015
Location
Valencia, -, Spain
Primary Industry
Biotechnology
About
Headquartered in Valencia, Spain, Quibim, S. L. specializes in artificial intelligence solutions tailored for medical imaging, enhancing diagnostic precision and aiding healthcare providers in patient outcomes. Quibim, S.
L. was established in 2015 in Valencia, Spain, focusing on AI-driven medical imaging solutions. The company does not have known subsidiaries or parent companies and has undergone strategic pivots to enhance its product offerings. Ángel Alberich-Bayarri is the founder and also serves as the CEO.
Quibim raised EUR 47. 9 mn in a Series A funding round on January 16, 2025, with support from investors such as Adara Ventures and Amadeus Capital Partners. The company has successfully completed a total of 9 investment deals to date. Quibim offers a range of advanced artificial intelligence products for medical imaging, including QP-Prostate®, QP-Brain®, QP-Liver®, and QP-Insights®.
These solutions aim to improve diagnostic accuracy and streamline data management for hospitals and research institutions primarily in North America and Europe. In the most recent fiscal year, 2023, Quibim reported revenues of EUR 2,094,654. 10, with an EBITDA of EUR -4,728,293. 80, reflecting their ongoing investment in product development and market expansion.
Following the successful Series A funding of EUR 47. 9 mn in January 2025, Quibim plans to utilize these resources to enhance its product pipeline and accelerate global growth. The company is particularly focused on expanding into the U. S.
market by forming partnerships with hospitals and pharmaceutical companies. With these initiatives, Quibim aims to solidify its presence in new regions and enhance its offerings in the medical imaging landscape.
Current Investors
Clave Capital, Ayce Capital, BioInfoGate S.L.
Primary Industry
Biotechnology
Sub Industries
Bioinformatics, Diagnostic, Medical & Imaging Laboratories, Medical Software
Website
www.quibim.com/
Verticals
Artificial Intelligence, Cloud Computing
Company Stage
Series A
Total Amount Raised
Subscriber access only
Quibim, S.L. - timeline of key events
Quibim, S.L. - financials
| Fiscal Year Ended | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 43,453.1 | 42,047.6 | 180,257.2 | 235,577.6 | 315,731 | 318,770.1 | - | - | - |
| % Revenue Growth (YoY) | - | (3.2%) | 328.7% | 30.7% | 34.0% | 1.0% | - | - | - |
| EBITDA (USD) | (50,105.8) | (160,248.4) | 81,686.1 | (171,718) | (385,182.7) | (918,310.8) | - | - | - |
| Operating Income (USD) | (50,445.1) | (162,865.5) | 39,262.1 | (264,879.3) | (750,453.1) | (1,340,203) | - | - | - |
| Operating Margin | (116.1%) | (387.3%) | 21.8% | (112.4%) | (237.7%) | (420.4%) | - | - | - |
| % EBITDA Margin | (115.3%) | (381.1%) | 45.3% | (72.9%) | (122.0%) | (288.1%) | - | - | - |
| NET Income (USD) | (51,040.8) | (163,451.9) | 37,261 | (273,308.9) | (772,969.7) | (1,357,745.7) | - | - | - |
| % Net Margin | (117.5%) | (388.7%) | 20.7% | (116.0%) | (244.8%) | (425.9%) | - | - | - |
Quibim, S.L. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.